



STATE OF WEST VIRGINIA  
DEPARTMENT OF HUMAN SERVICES  
BUREAU FOR MEDICAL SERVICES

Alex J. Mayer, PhD, MS, PMP  
Cabinet Secretary

Christy D. Donohue, CMC  
Commissioner

**Office of Pharmacy Services  
Prior Authorization Criteria  
VMAT Inhibitors**

**Xenazine® (tetrabenazine), Austedo® & Austedo XR® (deutetrabenazine), Ingrezza™ (valbenazine)**

**[Prior Authorization Request Form](#)**

**Xenazine (tetrabenazine)** is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with chorea associated with Huntington's disease.

**Austedo and Austedo XR (deutetrabenazine)** is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with chorea associated with Huntington's disease and for the treatment of tardive dyskinesia in adults.

**Ingrezza (valbenazine)** is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and for the treatment of adults with chorea associated with Huntington's disease.

**Xenazine (tetrabenazine) CRITERIA FOR APPROVAL:**

1. Patient must have a diagnosis of Chorea associated with Huntington's disease; **AND**
2. Must be prescribed by a M.D./D.O. or a specialty trained prescriber with a clinical specialty certification/degree in neurology; **AND**
3. The patient must be within the age range as recommended by the Food and Drug Administration (FDA) label; **AND**
4. Patient must have been evaluated and found not to be suicidal or have untreated/undertreated depression; **AND**
5. The prescribed dose must be provided and within dosing recommendations per the manufacturer label; **AND**
6. Patient must not be taking an MAOI (at least 14-days post-therapy), reserpine (must be >20 days post therapy) or any other concurrent VMAT2 inhibitor.

**Approval Duration:** Initial approval will be for 90 days.

**Criteria for reauthorization:** Continuation of therapy will be granted for 12 months.

1. Demonstrate continued documented compliance; **AND**
2. Documentation of positive clinical response and/or stabilization of symptoms must be provided.



## **Austedo, Austedo XR (deutetrabenazine) and Ingrezza (valbenazine) CRITERIA FOR APPROVAL:**

### **Initial\* Prior Authorization Criteria:**

- The patient must be within the age range as recommended by the FDA label; **AND**
- Patient must not be taking an MAOI (at least 14-days post-therapy), reserpine (must be >20 days post therapy) or any other concurrent VMAT2 inhibitor; **AND**
- Prescriber must provide a brief description of the medical necessity of therapy by documenting all target symptoms and their impact on the patient's function and activities of daily living; **AND**

### **Treatment of Chorea associated with Huntington's Disease (HD):**

1. Must be prescribed by a M.D./D.O. or a specialty trained prescriber with a clinical specialty certification/degree in neurology; **AND**
2. Patient must have been evaluated and found not to be suicidal or have untreated/undertreated depression; **AND**
3. All previous therapies must be documented along with their relative benefit. Unless contraindicated, the patient must have a documented 90-day trial, which resulted in intolerance or inadequate treatment response, to **Xenazine (tetrabenazine)**.

### **Treatment of Tardive Dyskinesia (TD):**

1. Must be prescribed by a M.D./D.O. or a specialty trained prescriber with a clinical specialty certification/degree in neurology or psychiatry; **AND**
2. Patient must provide a documented clinical diagnosis of tardive dyskinesia meeting DSM-V criteria including:
  - a) Involuntary athetoid or choreiform movements
  - b) History of treatment with a dopamine receptor blocking agent (DRBA) such as an antipsychotic or metoclopramide
  - c) Symptom duration lasting at least 8 weeks; **AND**
3. Prescriber must submit the results of an Abnormal Involuntary Movement Scale (AIMS) exam with every request for prior authorization of Austedo and Austedo XR; **AND**
4. Prescriber must submit documentation of all other therapies attempted and their associated benefit (**including relevant AIMS scores**).

**Approval Duration:** Initial approval will be for 90 days.

**Criteria for reauthorization:** Continuation of therapy will be granted for 12 months.

1. Demonstrate continued documented compliance; **AND**
2. Documentation of significant improvement in symptoms compared to that seen in previous therapy must be provided.